The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30+ peripheral T-cell lymphomas (PTCLs)

被引：0
|
作者：
Truemper, L. [1 ]
O'Connor, O. A. [2 ]
Pro, B. [3 ]
Illidge, T. M. [4 ]
Advani, R. H. [5 ]
Bartlett, N. L. [6 ]
Christensen, Haaber J. [7 ]
Morschhauser, F. [8 ]
Domingo-Domenech, E. [9 ]
Rossi, G. [10 ]
Kim, W. S. [11 ]
Feldman, T. A. [12 ]
Lennard, A. [13 ]
Belada, D. [14 ,15 ]
Illes, A. [16 ]
Tobinai, K. [17 ]
Tsukasaki, K. [18 ]
Yeh, S. -P. [19 ]
Shustov, A. R. [20 ]
Huettmann, A. [21 ]
Savage, K. J. [22 ,23 ]
Yuen, S. [24 ]
Iyer, S. [25 ]
Zinzani, P. L. [26 ]
Hua, Z. [27 ]
Little, M. [27 ]
Rao, S. [28 ]
Woolery, J. [28 ]
Manley, T. [28 ]
Horwitz, S. M. [29 ]
机构：
[1] Univ Med Gottingen, Dept Hematol & Oncol, Gottingen, Germany
[2] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA
[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth,Christie Hosp NHS Fdn Trust, NIHR Biomed Res Ctr,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[5] Stanford Canc Ctr, Blood & Marrow Transplant Program, Palo Alto, CA USA
[6] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[7] Odense Univ Hosp, Dept Hematol, Odense, Denmark
[8] CHRU Lille, Dept Hematol, Lille, France
[9] Inst Catala Oncol, Dept Hematol, Barcelona, Spain
[10] Azienda Osped Spedali Civili Brescia, Dept Hematol, Brescia, Italy
[11] Samsung Med Ctr, Seoul, South Korea
[12] Hackensack Univ Med Ctr, Hackensack, NJ USA
[13] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[14] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic
[15] Charles Univ Prague, Fac Med, Prague, Czech Republic
[16] Debreceni Egyet, Debrecen, Hungary
[17] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[18] Saitama Med Univ, Int Med Ctr, Dept Hematol, Saitama, Japan
[19] China Med Univ Hosp, Taichung, Taiwan
[20] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA
[21] Univ Klinikum Essen, Klin Hamatol, Essen, Germany
[22] Univ British Columbia, Dept Med Oncol, Vancouver, BC, Canada
[23] British Columbia Canc Agcy, Dept Med Oncol, Ctr Lymphoid Canc, Vancouver, BC, Canada
[24] Calvary Mater Newcastle Hosp, Dept Hematol, Waratah, Australia
[25] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
[27] Takeda Pharmaceut Int Co, Cambridge, MA USA
[28] Seattle Genet Inc, Bothell, WA USA
[29] Mem Sloan Kettering Canc Ctr, Dept Med, Basking Ridge, NJ USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V99
引用
收藏
页码：23 / 23
页数：1
相关论文
共 32 条
  • [1] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 10
  • [2] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim M.
    Fanale, Michelle A.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Lennard, Anne
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei R.
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Hua, Zhaowei
    Little, Meredith
    Rao, Shangbang
    Woolery, Joseph
    Manley, Thomas
    Truemper, Lorenz
    BLOOD, 2018, 132
  • [3] The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
    Iyer, Swaminathan
    Truemper, Lorenz
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana
    Menne, Tobias
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Miao, Harry
    Bunn, Veronica
    Fenton, Keenan
    Fanale, Michelle
    Puhlmann, Markus
    Horwitz, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S411 - S411
  • [4] The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Iyer, Swami P.
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Menne, Tobias
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei R.
    Huttmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Miao, Harry
    Bunn, Veronica
    Fenton, Keenan
    Fanale, Michelle A.
    Puhlmann, Markus
    Truemper, Lorenz
    BLOOD, 2020, 136
  • [5] The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
    Horwitz, Steven M.
    Savage, Kerry J.
    Timillidge
    Plyer, Swaminathan
    Advani, Ranjana
    Shustov, Andrei R.
    Bartlett, Nancy L.
    Pro, Barbara
    Jacobsen, Eric D.
    Koch, Raphael
    Eva, Domingo Domenech
    Fanale, Michelle A.
    Fenton, Keenan
    Campana, Frank
    Dong, Cassie
    Truemper, Lorenz
    BLOOD, 2021, 138
  • [6] Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2)
    Truemper, L.
    Pro, B.
    Horwitz, S.
    O'connor, O.
    Tilly, H.
    Choi, I.
    Gritti, G.
    Fox, C.
    Alpdogan, O.
    Mayer, J.
    Briones, J.
    Jacobsen, E.
    Pezzutto, A.
    Demeter, J.
    Gurion, R.
    Jurczak, W.
    Kuo, C. -Y.
    Opat, S.
    Little, M.
    Brown, L.
    Puhlmann, M.
    Illidge, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 119 - 119
  • [7] ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Truemper, L.
    O'Connor, O. A.
    Pro, B.
    Illidge, T.
    Advani, R.
    Bartlett, N. L.
    Christensen, J. H.
    Morschhauser, F.
    Domingo-Domenech, E.
    Rossi, G.
    Kim, W. S.
    Feldman, T.
    Menne, T.
    Belada, D.
    Illes, A.
    Tobinai, K.
    Tsukasaki, K.
    Yeh, S. P.
    Huettmann, A.
    Savage, K. J.
    Yuen, S.
    Iyer, S.
    Zinzani, P. L.
    Miao, H.
    Bunn, V
    Fenton, K.
    Fanale, M.
    Puhlmann, M.
    Horwitz, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 128 - 128
  • [8] An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant
    Savage, Kerry J.
    Horwitz, Steven M.
    Advani, Ranjana H.
    Christensen, Jacob H.
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Morschhauser, Franck
    Alpdogan, Onder
    Suh, Cheolwon
    Tobinai, Kensei
    Shustov, Andrei R.
    Trneny, Marek
    Yuen, Sam
    Zinzani, Pier Luigi
    Truemper, Lorenz
    Illidge, Timothy
    O'Connor, Owen
    Pro, Barbara
    Little, Meredith
    Bunn, Veronica
    Fenton, Keenan
    Manley, Thomas
    Iyer, Swaminathan P.
    BLOOD, 2019, 134
  • [9] Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) as Frontline Treatment for Patients with CD30-Expressing PERIPHERAL T-Cell Lymphomas (Echelon-2): Impact of Consolidative Stem Cell Transplant
    Trneny, Marek
    Savage, Kerry J.
    Horwitz, Steven M.
    Advani, Ranjana
    Christensen, Jacob H.
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Morschhauser, Franck
    Alpdogan, Onder
    Suh, Cheolwon
    Tobinai, Kensei
    Shustov, Andrei R.
    Yuen, Sam
    Zinzani, Pier Luigi
    Trumper, Lorenz
    Illidge, Timothy
    O'Connor, Owen
    Pro, Barbara
    Little, Meredith
    Bunn, Veronica
    Fenton, Keenan
    Manley, Thomas
    Iyer, Swaminathan P.
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 115 - 116
  • [10] PHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+MATURE T-CELL LYMPHOMAS (MTCL)
    Illidge, T.
    Pro, B.
    Truemper, L. H.
    Larsen, E. K.
    Huebner, D.
    Kennedy, D. A.
    O'Connor, O.
    ANNALS OF ONCOLOGY, 2014, 25
1234